AML with aberrant DNA methylation resulting from TET2 or IDH2 mutations is susceptible to 5-azacytidine or to IDH2 inhibitor in experimental models [8], demonstrating the feasibility of improving clinical outcomes of AML patients using novel targeted agents. This evidence concerns the gene IDH2 and acute myeloid leukemia.